[Featured Stock] Celltrion Rises Over 3%... Impact of Record High Sales

Celltrion is showing a strong gain of over 3% on the 26th. This is interpreted as investor sentiment reviving due to last year's record-high sales and expectations for performance growth this year.

As of 10:39 a.m. on the day, Celltrion's stock price is trading at 179,600 KRW, up 3.16% compared to the previous session.

The day before, Celltrion announced that its consolidated sales for last year reached 3.5573 trillion KRW, with an operating profit of 492 billion KRW. In particular, sales increased by 63.5% compared to the previous year, marking an all-time high. In the fourth quarter of last year, sales exceeded 1 trillion KRW for the first time in a single quarter, reaching 1.0636 trillion KRW.

Positive outlooks have also been made regarding this year's performance. Celltrion plans to launch five new products this year (Stelara, Xolair, Prolia, Eylea, Actemra). Lee Jisoo, a researcher at Daol Investment & Securities, said, “Strong performance is expected due to stable sales growth of existing biosimilars, an increase in the sales proportion of high-margin items such as Remsima SC and Uplima, and the effect of new product sales,” adding, “Improvement in cost ratio is also expected due to the depletion of inventory assets at Celltrion Healthcare.”

This content was produced with the assistance of AI translation services.